{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:19:31Z","timestamp":1787840371412,"version":"build-2784847793"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n To investigate IPD regimen effect on vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) levels in elderly patients with recurrent multiple myeloma (MM).<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Eighty-two elderly patients with relapsed multiple myeloma in our hospital from January 2019 to December 2021 were selected and randomly divided into TD group and IPD group, 41 cases in each group. The TD group was treated with thalidomide + dexamethasone, while the IPD group was treated with ixazomib + pomalidomide + dexamethasone. The treatment effect and the changes of VEGF and IL-6, TNF-\u03b1, levels before treatment, 6 months, and 12 months after treatment were compared by the log-rank test. The Kaplan-Meier method determined the progression-free survival (PFS) of patients.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The clinical efficacy distribution of IPD was better than that of the TD group (Z = 2.407,\n P<\/jats:italic>\n = 0.016). No significant difference was showed in serum VEGF and IL-6, TNF-\u03b1, concentrations before treatment (T0) (\n P<\/jats:italic>\n > 0.05). The serum concentrations of VEGF and IL-6, TNF-\u03b1, in the IPD group were lower at 6 months and 12 months after treatment. The incidence of progression in the IPD group was 9.76% (4\/41), and the estimated time of no progression was 11.73 \u00b1 0.21 months. The incidence of progression was 19.51% (8\/41) in the TD group, and the estimated time without progression was 10.95 \u00b1 0.38 months, showing no significant difference (\u03c7\n 2<\/jats:sup>\n = 1.718,\n P<\/jats:italic>\n = 0.190).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n IPD regimen for relapsed elderly multiple myeloma has the characteristics of improving clinical efficacy and inhibiting VEGF and IL-6, TNF-\u03b1, concentrations increase. However, compared with TD therapy, IPD regimen has similar effects on the risk and time of progression.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijc.ijc_51_24","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T17:00:21Z","timestamp":1754931621000},"page":"203-208","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["IPD regimen effect on the levels of VEGF and IL-6 in elderly patients with recurrent multiple myeloma"],"prefix":"10.4103","volume":"62","author":[{"given":"Huiying","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Hematology, Suzhou Hospital of Anhui Medical University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyu","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Suzhou Hospital of Anhui Medical University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Suzhou Hospital of Anhui Medical University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"R1-20250812","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/2159-8290.CD-22-0482","article-title":"MinimuMM-seq:Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology","volume":"13","author":"Dutta","year":"2023","journal-title":"Cancer Discov"},{"key":"R2-20250812","doi-asserted-by":"crossref","first-page":"9604","DOI":"10.1002\/cam4.5737","article-title":"The evolving diagnosis and treatment paradigms of multiple myeloma in China:15 years'experience of 1256 patients in a national medical center","volume":"12","author":"Yang","year":"2023","journal-title":"Cancer Med"},{"key":"R3-20250812","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2217\/fon-2022-1018","article-title":"Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma","volume":"19","author":"Hlavacek","year":"2023","journal-title":"Future Oncol"},{"key":"R4-20250812","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1186\/s12885-022-10101-9","article-title":"The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma:A prospective observational study","volume":"22","author":"Fischer","year":"2022","journal-title":"BMC Cancer"},{"key":"R5-20250812","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/CAD.0000000000001520","article-title":"Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma","volume":"35","author":"Alhaj Moustafa","year":"2024","journal-title":"Anticancer Drugs"},{"key":"R6-20250812","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-023-00804-y","article-title":"Clinical evidence for immune-based strategies in early-line multiple myeloma:Current challenges in decision-making for subsequent therapy","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"R7-20250812","first-page":"5248","article-title":"A comparison of the efficacy and safety of ixazomib and lenalidomide combined with dexamethasone in the treatment of multiple myeloma","volume":"13","author":"Zheng","year":"2021","journal-title":"Am J Transl Res"},{"key":"R8-20250812","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3390\/cancers15071929","article-title":"30 Years of improved survival in non-transplant-eligible newly diagnosed multiple myeloma","volume":"15","author":"Chacon","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R9-20250812","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17474086.2020.1804356","article-title":"Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma:An evidence-based review","volume":"13","author":"Sanchez","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"R10-20250812","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s10198-020-01219-3","article-title":"Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany","volume":"21","author":"Basic","year":"2020","journal-title":"Eur J Health Econ"},{"key":"R11-20250812","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.3390\/cancers13112712","article-title":"Rapid progress in immunotherapies for multiple myeloma:An updated comprehensive review","volume":"13","author":"Nishida","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R12-20250812","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12185-023-03601-2","article-title":"Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors","volume":"118","author":"Nakaue","year":"2023","journal-title":"Int J Hematol"},{"key":"R13-20250812","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41375-023-01809-z","article-title":"Alternate-day dosing of pomalidomide in relapsed\/refractory multiple myeloma:A multicenter, single-arm phase 2 trial","volume":"37","author":"Zander","year":"2023","journal-title":"Leukemia"},{"key":"R14-20250812","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjh.18772","article-title":"Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma","volume":"201","author":"Garderet","year":"2023","journal-title":"Br J Haematol"},{"key":"R15-20250812","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ajh.26866","article-title":"Quality of life and symptoms among patients with relapsed\/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice","volume":"98","author":"Sanchorawala","year":"2023","journal-title":"Am J Hematol"},{"key":"R16-20250812","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO):An open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"R17-20250812","doi-asserted-by":"crossref","first-page":"114727","DOI":"10.1016\/j.bcp.2021.114727","article-title":"Thalidomide alleviates neuropathic pain through microglial IL-10\/\u03b2-endorphin signaling pathway","volume":"192","author":"Deng","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"R18-20250812","doi-asserted-by":"crossref","first-page":"17319","DOI":"10.1038\/s41598-020-74352-x","article-title":"Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23","volume":"10","author":"Mulcrone","year":"2020","journal-title":"Sci Rep"},{"key":"R19-20250812","doi-asserted-by":"crossref","first-page":"1169071","DOI":"10.3389\/fimmu.2023.1169071","article-title":"A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed\/refractory multiple myeloma patients treated with CAR-T cells","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"R20-20250812","doi-asserted-by":"crossref","first-page":"115","DOI":"10.14715\/cmb\/2021.67.4.13","article-title":"Evaluation of the efficacy of MST-312, as a telomerase inhibitor, in the treatment of patients with multiple myeloma after stem cell transplantation","volume":"67","author":"Zhou","year":"2022","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"R21-20250812","first-page":"1474","article-title":"IL-6 Regulates the chemosensitivity of drug-resistant multiple myeloma cell lines to bortezomib through STAT3\/notch signaling pathway","volume":"30","author":"Liu","year":"2022","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"R22-20250812","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1021\/acs.jproteome.1c00007","article-title":"Proteomics-based approach reveals the involvement of SERPINB9 in recurrent and relapsed multiple myeloma","volume":"20","author":"Chen","year":"2021","journal-title":"J Proteome Res"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_51_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:21:35Z","timestamp":1787836895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_51_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_51_24","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-01-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}